Immuneering Announces Initial Phase 2a Data From First Five Patients Treated With IMM-1-104 Plus Modified Gemcitabine/Nab-Paclitaxel; Showed 40% ORR And Disease Control Rate Of 80%
Portfolio Pulse from Benzinga Newsdesk
Immuneering has announced initial Phase 2a data for its treatment IMM-1-104 combined with modified Gemcitabine/Nab-Paclitaxel. The results from the first five patients show a 40% overall response rate (ORR) and an 80% disease control rate.
September 12, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immuneering's initial Phase 2a data for IMM-1-104 shows promising results with a 40% ORR and 80% disease control rate, potentially boosting investor confidence.
The positive initial results from the Phase 2a trial of IMM-1-104 are likely to boost investor confidence in Immuneering, as they indicate potential efficacy of the treatment. This could lead to a positive short-term impact on IMRX stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100